EurekAlert! -
28 Jun 2019 06:00
(Université de Genève) By testing a variety of gold nanoparticles, researchers (UNIGE and Swansea) are providing first evidence of their impact upon human B lymphocytes -- the immune cells responsible for antibody production. The use of these nanoparticles is expected to improve the efficacy of pharmaceutical products while limiting potential adverse effects. These results will lead to the development of more targeted and better tolerated therapies, particularly in the field of oncology.
Share this Article